The deal reflects Lilly’s strategic push to strengthen its neuroscience portfolio through orexin-based therapeutics.
Intelligence for the Dealmaking Community since 1965
After clicking on a story, use the back arrow in your browser to return to your search results. Use phrases "in quotes" or the tools below to better filter your results.